Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy
Abstract
:1. Introduction
2. Radiomics in Head and Neck Cancer
Study Type/Goal | Imaging Modality/Radiomic Features | Observations/Conclusions |
---|---|---|
Radiomic Studies for Outcome Prediction: Tumour Control | ||
Staging and risk stratification model in oropharyngeal carcinomas (Cheng et al., 2013) [23] | PET/CT imaging Grey-level co-occurrence matrix, uniformity, and coherence | A risk stratification strategy was developed based on total lesion glycolysis (TLG) and uniformity. TLG, uniformity, and HPV positivity are significantly associated with overall survival. |
Prognostic imaging biomarkers for overall survival (Parmar et al., 2015) [24] | CT imaging First-order intensity statistics, shape, and volume textural featuresArea under receiver operating characteristics curve (AUC) used to quantify the prognostic performance of different feature selection | Three feature selection methods—minimum redundancy maximum relevance, mutual information feature selection, and conditional infomax feature extraction had high prognostic stability and performance for the prediction of overall survival. |
Prediction of local control using pre-treatment PET vs. CT (Bogowicz et al., 2017) [6] | PET/CT imaging CT density, HLH intensity, grey-level size zone texture matrices, and spherical disproportion | The model overestimated tumour control probability in high-risk patients. Combined PET/CT added no extra value when compared to either imaging method alone. |
Risk prediction models of locoregional recurrences and distant metastases (Vallieres et al., 2017) [7] | CT imaging Large zone high grey-level emphasis; zone size non-uniformity | No significant correlation was found between radiomic features and locoregional recurrence. Image-derived features combined with clinical variables offer the highest predictive values. |
Risk prediction models of all-cause mortality, local failure & distant metastasis (Folkert et al., 2017) [8] | CT imaging Image features: statistical, shape, and texture | Multiparametric models had the strongest predictive power. The local failure model demonstrated robustness when conveyed onto independent patient cohorts. |
Radiomic Studies for Outcome Prediction: Normal Tissue Toxicity | ||
Assessment of structural changes in parotid glands (Scalco et al., 2013) [9] | CT imaging Textural features and gland volume | Variations in mean intensity and fractal dimension (after the second and last week of radiotherapy) were the best predictors of parotid shrinkage. |
Early prediction of parotid shrinkage and toxicity (Pota et al., 2017) [10] | CT imaging Textural features, spatial patterns, fractal dimensions, and gland volume combined with fuzzy classification | The final parotid shrinkage rate strongly correlated with 12-month xerostomia: glands that presented strong volume variation post-radiotherapy could be less affected by late xerostomia. |
Prediction of radiation-induced xerostomia and sticky saliva (Van Dijk et al., 2017) [11] | CT imaging Geometric features, CT intensity, and textural features | Prediction of 12-month xerostomia and sticky saliva were improved by the addition to the initial CT image biomarkers of the short-run emphasis (quantifies heterogeneity of parotid) and of the maximum CT intensity of the submandibular gland (gland density). |
Prediction of late xerostomia using parotid gland fat (Van Dijk et al., 2018) [12] | MR imaging T1-weighted MR-image-based intensity (90th intensity percentile) and textural features | The ratio of fat-to-functional-parotid-tissue is associated with 12-month xerostomia. MR-based radiomics improved prediction. |
Prediction of severe late xerostomia (Nardone et al., 2018) [25] | CT imaging Textural features: grey-level co-occurrence matrix (GLCM), neighbourhood grey-level dependence matrix (NGLDM), grey-level run length matrix (GLRLM), grey-level zone length matrix (GLZLM), sphericity, indices from the grey-level histogram, and parotid volume | Parameters with the strongest correlation with severe chronic xerostomia: V30, mean dose, kurtosis, grey-level co-occurrence matrix (GLCM), and run length non-uniformity (RLNU). CT texture analysis could allow for the enhancement of dose constraints to organs at risk to avoid severe side effects. |
Multivariable modelling study of chemotherapy-induced hearing loss (Abdollahi et al., 2018) [21] | CT imaging Textural features with highest predictive power: intensity histogram (IH) and grey-level co-occurrence matrix (GLCM) | Ten machine learning classifiers used for radiomic feature selection, classification, and prediction, with over 70% accuracy. No single algorithm showed superiority for all problems. CT image features of cochlea can serve as biomarkers for predicting hearing loss after therapy. |
Early prediction of acute xerostomia during therapy (Wu et al., 2018) [26] | CT imaging Histogram-based features: mean CT number (MCTN), volume, skewness, kurtosis, and entropy | Daily CT images analysis during IMRT indicated that changes in gland volume or MCTN are not correlated with grade of xerostomia if considered separately but when combined in a CT-based xerostomia score model. This can predict severity with a precision of 100% at the 5th week of therapy. |
Assessment of whole-brain white matter injury after radiotherapy (Leng et al., 2019) [22] | MR diffusion tensor imaging Fractional anisotropy (FA) and FA skeleton matrix | Post-therapy decreased FA values (that quantify the degree of water diffusion in cerebral white matter) showed microstructure damage of the white matter. Radiation brain injury in HNC patients can be quantified using MR diffusion-tensor-based radiomics. |
Predictive model of acute radiation-induced xerostomia (Sheikh et al., 2019) [13] | CT and MR imaging Shape, first-order statistics, grey-level co-occurrence matrix (GLCM), grey-level run length matrix (GLRLM), and grey-level size zone matrix (GLSZM)Model performance improved when DVH was combined with CT and MRI features | Higher-order texture features for salivary glands were key predictors of xerostomia. MRI: patients with xerostomia appear more heterogeneous and hypointense. CT: submandibular glands of patient with xerostomia appear more hypodense and heterogeneous. Baseline CT and MRI features can potentially reflect baseline salivary gland function and the risk of radiation-induced effects. |
Longitudinal study on post-radiotherapy parotid gland changes in nasopharyngeal cancer patients (Wu et al., 2020) [14] | MR and ultrasound (US) imaging MRI features: volumeUS features: echogenicity and hemodynamic parameters (resistive index, pulsatility index, and peak diastolic and end-diastolic velocity) | Parotid and submandibular gland shrinkage associated with xerostomia was observed post-radiotherapy (IMRT), with most significant changes detected after 6 months. Mild correlation found between gland dose and post-radiotherapy gland volume. |
3. Dosiomics in Head and Neck Cancer
4. Pharmacogenomics and Pharmacogenetics in Head and Neck Cancer
4.1. Introduction—Chemotherapy in Head and Neck Cancer
4.2. Pharmacomics—Towards Personalised Chemotherapy
5. Chemoradiotherapy Response Monitoring Using Delta-Radiomics
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Pulte, D.; Brenner, H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. Oncologist 2010, 15, 994–1001. [Google Scholar] [CrossRef] [Green Version]
- van der Heijden, M.; Essers, P.B.M.; de Jong, M.C.; de Roest, R.H.; Sanduleanu, S.; Verhagen, C.V.M.; Hamming-Vrieze, O.; Hoebers, F.; Lambin, P.; Bartelink, H.; et al. Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. Front. Oncol. 2020, 9, 1470. [Google Scholar] [CrossRef]
- Lambin, P.; Rios-Velazquez, E.; Leijenaar, R.; Carvalho, S.; van Stiphout, R.G.; Granton, P.; Zegers, C.M.L.; Gillies, R.; Boellard, R.; Dekker, A.; et al. Radiomics: Extracting more infor-mation from medical images using advanced feature analysis. Eur. J. Cancer 2012, 48, 441–446. [Google Scholar] [CrossRef] [Green Version]
- Yu, H.; Caldwell, C.; Mah, K.; Poon, I.; Balogh, J.; MacKenzie, R.; Khaouam, N.; Tirona, R. Automated Radiation Targeting in Head-and-Neck Cancer Using Region-Based Texture Analysis of PET and CT Images. Int. J. Radiat. Oncol. 2009, 75, 618–625. [Google Scholar] [CrossRef] [PubMed]
- Wu, B.; Khong, P.-L.; Chan, T. Automatic detection and classification of nasopharyngeal carcinoma on PET/CT with support vector machine. Int. J. Comput. Assist. Radiol. Surg. 2012, 7, 635–646. [Google Scholar] [CrossRef] [Green Version]
- Bogowicz, M.; Riesterer, O.; Stark, L.S.; Studer, G.; Unkelbach, J.; Guckenberger, M.; Tanadini-Lang, S. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma. Acta Oncol. 2017, 56, 1531–1536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vallieres, M.; Kay-Rivest, E.; Perrin, L.J.; Liem, X.; Furstoss, C.; Aerts, H.J.W.L.; Khaouam, N.; Nguyen-Tan, P.F.; Wang, C.-S.; Sultanem, K.; et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci. Rep. 2017, 7, 10117. [Google Scholar] [CrossRef] [Green Version]
- Folkert, M.R.; Setton, J.; Apte, A.P.; Grkovski, M.; Young, R.J.; Schöder, H.; Thorstad, W.L.; Lee, N.Y.; Deasy, J.O.; Oh, J.H. Predictive modeling of outcomes following definitive chemoradiotherapy for oropha-ryngeal cancer based on FDG-PET image characteristics. Phys. Med. Biol. 2017, 62, 5327–5343. [Google Scholar] [CrossRef] [PubMed]
- Scalco, E.; Fiorino, C.; Cattaneo, G.M.; Sanguineti, G.; Rizzo, G. Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy. Radiother. Oncol. 2013, 109, 384–387. [Google Scholar] [CrossRef]
- Pota, M.; Scalco, E.; Sanguineti, G.; Farneti, A.; Cattaneo, G.M.; Rizzo, G.; Esposito, M. Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on CT radiomics and fuzzy classification. Artif. Intell. Med. 2017, 81, 41–53. [Google Scholar] [CrossRef]
- van Dijk, L.V.; Brouwer, C.L.; Van Der Schaaf, A.; Burgerhof, J.G.M.; Beukinga, R.J.; Langendijk, J.A.; Sijtsema, N.M.; Steenbakkers, R.J.H.M. CT image biomarkers to improve patient-specific prediction of radiation- induced xerostomia and sticky saliva. Radiother. Oncol. 2017, 122, 185–191. [Google Scholar] [CrossRef] [Green Version]
- van Dijk, L.V.; Thor, M.; Steenbakkers, R.J.; Apte, A.; Zhai, T.-T.; Borra, R.; Noordzij, W.; Estilo, C.; Lee, N.; Langendijk, J.A.; et al. Parotid gland fat related Magnetic Resonance Image biomarkers improve prediction of late radiation-induced xerostomia. Radiother. Oncol. 2018, 128, 459–466. [Google Scholar] [CrossRef] [PubMed]
- Sheikh, K.; Lee, S.H.; Cheng, Z.; Lakshminarayanan, P.; Peng, L.; Han, P.; McNutt, T.R.; Quon, H.; Lee, J. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands. Radiat. Oncol. 2019, 14, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Wu, V.W.C.; Ying, M.T.; Kwong, D.L.; Khong, P.L.; Wong, G.K.; Tam, S.Y. A longitudinal study on parotid and submandibular gland changes assessed by magnetic resonance imaging and ultrasonography in post-radiotherapy nasopharyngeal cancer patients. BJR Open 2020, 2, 20200003. [Google Scholar] [CrossRef]
- Bogowicz, M.; Pavic, M.; Riesterer, O.; Finazzi, T.; Schüler, H.G.; Holz-Sapra, E.; Rudofsky, L.; Basler, L.; Spaniol, M.; Ambrusch, A.; et al. Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma—Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. Front. Oncol. 2021, 11. [Google Scholar] [CrossRef]
- Aerts, H.J.; Velazquez, E.R.; Leijenaar, R.T.; Parmar, C.; Grossmann, P.; Carvalho, S.; Bussink, J.; Monshouwer, R.; Haibe-Kains, B.; Rietveld, D.; et al. Decoding tumour phenotype by noninvasive imaging using a quantitative ra-diomics approach. Nat. Commun. 2014, 5, 4006. [Google Scholar] [CrossRef] [PubMed]
- Ang, K.K.; Sturgis, E.M. Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell Carcinoma. Semin. Radiat. Oncol. 2012, 22, 128–142. [Google Scholar] [CrossRef] [PubMed]
- Cantrell, S.C.; Peck, B.W.; Li, G.; Wei, Q.; Sturgis, E.M.; Ginsberg, L.E. Differences in Imaging Characteristics of HPV-Positive and HPV-Negative Oropharyngeal Cancers: A Blinded Matched-Pair Analysis. Am. J. Neuroradiol. 2013, 34, 2005–2009. [Google Scholar] [CrossRef]
- Buch, K.; Fujita, A.; Li, B.; Kawashima, Y.; Qureshi, M.M.; Sakai, O. Using Texture Analysis to Determine Human Papillomavirus Status of Oropharyngeal Squamous Cell Carcinomas on CT. Am. J. Neuroradiol. 2015, 36, 1343–1348. [Google Scholar] [CrossRef] [Green Version]
- Fujita, A.; Buch, K.; Li, B.; Kawashima, Y.; Qureshi, M.M.; Sakai, O. Difference Between HPV-Positive and HPV-Negative Non-Oropharyngeal Head and Neck Cancer: Texture Analysis Features on CT. J. Comput. Assist. Tomogr. 2016, 40, 43–47. [Google Scholar] [CrossRef]
- Abdollahi, H.; Mostafaei, S.; Cheraghi, S.; Shiri, I.; Rabi Mahdavi, S.; Kazemnejad, A. Cochlea CT radiomics predicts chemoradio-therapy induced sensorineural hearing loss in head and neck cancer patients: A machine learning and multi-variable mod-elling study. Phys. Med. 2018, 45, 192–197. [Google Scholar] [CrossRef] [PubMed]
- Leng, X.; Fang, P.; Lin, H.; Qin, C.; Tan, X.; Liang, Y.; Zhang, C.; Wang, H.; An, J.; Wu, D.; et al. Application of a machine learning method to whole brain white matter injury after radiotherapy for nasopharyngeal carcinoma. Cancer Imaging 2019, 19, 19. [Google Scholar] [CrossRef]
- Cheng, N.-M.; Fang, Y.-H.D.; Chang, J.T.-C.; Huang, C.-G.; Tsan, D.-L.; Ng, S.-H.; Wang, H.-M.; Lin, C.-Y.; Liao, C.-T.; Yen, T.-C. Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma. J. Nucl. Med. 2013, 54, 1703–1709. [Google Scholar] [CrossRef] [Green Version]
- Parmar, C.; Grossmann, P.; Rietveld, D.; Rietbergen, M.M.; Lambin, P.; Aerts, H.J.W.L. Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. Front. Oncol. 2015, 5, 272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nardone, V.; Tini, P.; Nioche, C.; Mazzei, M.A.; Carfagno, T.; Battaglia, G.; Pastina, P.; Grassi, R.; Sebaste, L.; Pirtoli, L. Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT. La Radiol. Med. 2018, 123, 415–423. [Google Scholar] [CrossRef]
- Wu, H.; Chen, X.; Yang, X.; Tao, Y.; Xia, Y.; Deng, X.; Zheng, C.; Robbins, J.; Schultz, C.; Li, X.A. Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT. Int. J. Radiat. Oncol. 2018, 102, 1308–1318. [Google Scholar] [CrossRef]
- Buciuman, N.; Marcu, L.G. Dosimetric justification for the use of volumetric modulated arc therapy in head and neck cancer—A systematic review of the literature. Laryngoscope 2021, 6, 999–1007. [Google Scholar] [CrossRef]
- Beetz, I.; Schilstra, C.; Burlage, F.R.; Koken, P.W.; Doornaert, P.; Bijl, H.P.; Chouvalova, O.; Leemans, C.R.; de Bock, G.H.; Christianen, M.E.M.C.; et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of dosi-metric and clinical factors. Radiother. Oncol. 2012, 105, 86–93. [Google Scholar] [CrossRef] [Green Version]
- Gabryś, H.S.; Buettner, F.; Sterzing, F.; Hauswald, H.; Bangert, M. Parotid gland mean dose as a xerostomia predictor in low-dose domains. Acta Oncol. 2017, 56, 1197–1203. [Google Scholar] [CrossRef]
- Buettner, F.; Miah, A.B.; Gulliford, S.L.; Hall, E.; Harrington, K.; Webb, S.; Partridge, M.; Nutting, C.M. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother. Oncol. 2012, 103, 82–87. [Google Scholar] [CrossRef]
- Gabryś, H.S.; Buettner, F.; Sterzing, F.; Hauswald, H.; Bangert, M. Design and Selection of Machine Learning Methods Using Ra-diomics and Dosiomics for Normal Tissue Complication Probability Modeling of Xerostomia. Front Oncol. 2018, 8, 35. [Google Scholar] [CrossRef] [PubMed]
- Wu, A.; Li, Y.; Qi, M.; Lu, X.; Jia, Q.; Guo, F.; Dai, Z.; Liu, Y.; Chen, C.; Zhou, L.; et al. Dosiomics improves prediction of locoregional recurrence for intensity modu-lated radiotherapy treated head and neck cancer cases. Oral Oncol. 2020, 104, 104625. [Google Scholar] [CrossRef] [PubMed]
- Petit, C.; Lacas, B.; Pignon, J.P.; Le, Q.T.; Grégoire, V.; Grau, C.; Hackshaw, A.; Zackrisson, B.; Parmar, M.K.B.; Lee, J.-W.; et al. MACH-NC and MARCH Collaborative Groups. Chemothera-py and radiotherapy in locally advanced head and neck cancer: An individual patient data network meta-analysis. Lancet Oncol. 2021, 22, 727–736. [Google Scholar] [CrossRef]
- Marcu, L.; Bezak, E.; Olver, I.; Van Doorn, T. Tumour resistance to cisplatin: A modelling approach. Phys. Med. Biol. 2004, 50, 93–102. [Google Scholar] [CrossRef] [PubMed]
- Golan Berman, H.; Chauhan, P.; Shalev, S.; Hassanain, H.; Parnas, A.; Adar, S. Genomic Characterization of Cisplatin Response Uncovers Priming of Cisplatin-Induced Genes in a Resistant Cell Line. Int. J. Mol. Sci. 2021, 22, 5814. [Google Scholar] [CrossRef]
- Moreira, J.; Tobias, A.; O’Brien, M.P.; Agulnik, M. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Drugs 2017, 77, 843–857. [Google Scholar] [CrossRef]
- Marcu, L.G. Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence. Crit. Rev. Oncol. 2016, 103, 27–36. [Google Scholar] [CrossRef]
- Rosenberg, A.J.; Vokes, E.E. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncol. 2021, 26, 40–48. [Google Scholar] [CrossRef]
- Giefing, M.; Wierzbicka, M.; Szyfter, K.; Brenner, J.; Braakhuis, B.; Brakenhoff, R.; Bradford, C.; Sørensen, J.A.; Rinaldo, A.; Rodrigo, J.P.; et al. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. Eur. J. Cancer 2016, 55, 147–157. [Google Scholar] [CrossRef] [Green Version]
- Stupack, D.G. Caspase-8 as a therapeutic target in cancer. Cancer Lett. 2013, 332, 133–140. [Google Scholar] [CrossRef] [Green Version]
- Yamano, Y.; Uzawa, K.; Saito, K.; Nakashima, D.; Kasamatsu, A.; Koike, H.; Kouzu, Y.; Shinozuka, K.; Nakatani, K.; Negoro, K.; et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int. J. Cancer 2010, 126, 437–449. [Google Scholar] [CrossRef]
- Huang, Z.; Wang, L.; Wang, Y.; Zhuo, Y.; Li, H.; Chen, J.; Chen, W. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J. Oral Pathol. Med. 2013, 42, 541–546. [Google Scholar] [CrossRef] [PubMed]
- Ma, C.; Wang, J.; Fan, L.; Guo, Y. Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK/ERK signaling pathway. Exp. Mol. Pathol. 2017, 102, 59–64. [Google Scholar] [CrossRef] [PubMed]
- Govindan, S.V.; Kulsum, S.; Pandian, R.S.; Das, D.; Seshadri, M.; Hicks, W., Jr.; Kuriakose, M.A.; Suresh, A. Establishment and character-ization of triple drug resistant head and neck squamous cell carcinoma cell lines. Mol. Med. Rep. 2015, 12, 3025–3032. [Google Scholar] [CrossRef]
- Tamatani, T.; Ferdous, T.; Takamaru, N.; Hara, K.; Kinouchi, M.; Kuribayashi, N.; Ohe, G.; Uchida, D.; Nagai, H.; Fujisawa, K.; et al. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells. Int. J. Oncol. 2012, 41, 1148–1156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vaezi, A.; Wang, X.; Buch, S.; Gooding, W.; Wang, L.; Seethala, R.R.; Weaver, D.T.; D’Andrea, A.D.; Argiris, A.; Romkes, M.; et al. XPF expression correlates with clinical outcome in squa-mous cell carcinoma of the head and neck. Clin. Cancer Res. 2011, 17, 5513–5522. [Google Scholar] [CrossRef] [Green Version]
- Zhou, Z.; Zhang, L.; Xie, B.; Wang, X.; Yang, X.; Ding, N.; Zhang, J.; Liu, Q.; Tan, G.; Feng, D.; et al. FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition. Cancer Lett. 2015, 363, 137–145. [Google Scholar] [CrossRef]
- Dhawan, D.; Panchal, H.; Shukla, S.; Padh, H. Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: A preliminary study. Indian J. Med Res. 2013, 137, 125–129. [Google Scholar]
- Meulendijks, D.; Henricks, L.M.; Sonke, G.S.; Deenen, M.J.; Froehlich, T.K.; Amstutz, U.; Largiadèr, C.R.; Jennings, B.A.; Marinaki, A.M.; Sanderson, J.D.; et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic re-view and meta-analysis of individual patient data. Lancet Oncol. 2015, 16, 1639–1650. [Google Scholar] [CrossRef]
- Henricks, L.; Lunenburg, C.A.T.C.; de Man, F.; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.-J.; Baars, A.; Dezentjé, V.O.; Imholz, A.L.T.; et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis. Lancet Oncol. 2018, 19, 1459–1467. [Google Scholar] [CrossRef]
- Matsusaka, S.; Lenz, H.-J. Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin. Drug Metab. Toxicol. 2015, 11, 811–821. [Google Scholar] [CrossRef]
- Just, K.S.; Steffens, M.; Swen, J.J.; Patrinos, G.P.; Guchelaar, H.J.; Stingl, J.C. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical im-plementation project Ubiquitous Pharmacogenomics (U-PGx). Eur. J. Clin. Pharmacol. 2017, 73, 1247–1252. [Google Scholar] [CrossRef]
- Williams, M.S. Early Lessons from the Implementation of Genomic Medicine Programs. Annu. Rev. Genom. Hum. Genet. 2019, 20, 389–411. [Google Scholar] [CrossRef] [PubMed]
- Lazzeroni, M.; Ureba, A.; Wiedenmann, N.; Nicolay, N.H.; Mix, M.; Thomann, B.; Baltas, D.; Toma-Dasu, I.; Grosu, A.L. Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer. Phys. Imaging Radiat. Oncol. 2021, 17, 100–105. [Google Scholar] [CrossRef] [PubMed]
- Sörensen, A.; Carles, M.; Bunea, H.; Majerus, L.; Stoykow, C.; Nicolay, N.H.; Wiedenmann, N.E.; Vaupel, P.; Meyer, P.T.; Grosu, A.L.; et al. Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1056–1064. [Google Scholar] [CrossRef] [PubMed]
- Bruixola, G.; Remacha, E.; Jiménez-Pastor, A.; Dualde, D.; Viala, A.; Montón, J.V.; Ibarrola-Villava, M.; Alberich-Bayarri, Á.; Cervantes, A. Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges. Cancer Treat. Rev. 2021, 99, 102263. [Google Scholar] [CrossRef] [PubMed]
Resistance to Chemotherapy Agent/Group of Agents | Gene Mutation Responsible for Chemoresistance | Normal Function of the Gene |
---|---|---|
Platinum compounds (cisplatin and carboplatin) | Copper transporter receptor 1 (CTR1) (Govindan et al., 2015) [44] | Major copper influx transporter in cells |
Excision repair cross-complementation group 1 (ERCC1) (Govindan et al., 2015) [44] | Critical role within the nucleotide excision repair system of DNA | |
Excision repair cross-complementation group 4 XPF (ERCC4) (Vaezi et al., 2011) [46] | Protein involved in DNA binding and protein–protein interaction | |
Lumican (LUM) (Yamano et al., 2010) [41] | Proteoglycan involved in epithelial cell migration and tissue repair | |
Cyclic nucleotide phosphodiesterase type 3 (PDE3B) (Yamano et al., 2010) [41] | Intracellular messengers that regulate numerous signalling pathways | |
Platelet-derived growth factor C (PDGF-C) (Yamano et al., 2010) [41] | Important role in connective tissue growth and function. Belongs to the PDGF/vascular endothelial growth factor family | |
Neuregulin-1 (NRG1) (Yamano et al., 2010) [41] | A glycoprotein produced in a variety of isoforms that induce cell growth and differentiation | |
Protein kinase D (PKD2) (Yamano et al., 2010) [41] | Propagates growth factor receptors at the cell surface | |
Emmprin (CD147) (Huang et al., 2013, and Ma et al., 2017) [42,43] | Extracellular matrix metalloproteinase inducer | |
Antimetabolites (5-FU) | Thymidylate synthase (TS) (Govindan et al., 2015) [44] | Key enzyme in DNA biosynthesis |
Taxanes (docetaxel and paclitaxel) | Caspase-8 (CASP8) (Stupack et al., 2013) [40] | Initiates programmed cell death |
Forkhead box protein C2 (FOXC2) (Zhou et al., 2015) [47] | Role in the development of mesenchymal tissues |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marcu, L.G.; Marcu, D.C. Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy. J. Pers. Med. 2021, 11, 1094. https://doi.org/10.3390/jpm11111094
Marcu LG, Marcu DC. Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy. Journal of Personalized Medicine. 2021; 11(11):1094. https://doi.org/10.3390/jpm11111094
Chicago/Turabian StyleMarcu, Loredana G., and David C. Marcu. 2021. "Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy" Journal of Personalized Medicine 11, no. 11: 1094. https://doi.org/10.3390/jpm11111094